How treatment before surgery affects complications in colorectal cancer surgery
Compares complications and small blood vessels in colorectal cancer patients with and without earlier treatment.
Plain-language title generated from the registry record
Registry title: Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer
Key facts
- Where
- Osijek, CroatiaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with colorectal cancer who are planned for surgery. Some have had treatment before surgery (neoadjuvant therapy) and some go straight to surgery.
- Age
- 18 years or older
- Sex
- Women and men can join
- Disease stage
- Colorectal cancer confirmed by tissue testing. Surgery is planned, either keyhole (laparoscopic) or open. ASA class II or III.
- Earlier treatment
- One group has had neoadjuvant therapy before surgery. The comparison group has not had it.
Main reasons for not taking part
- Under 18 years old
- Cannot understand the study or give consent
- Emergency surgery
- Long-term corticosteroid treatment
- Not conscious or not oriented
Read by machine on 9 November 2026.
Where in Croatia
- KBC OsijekOsijek, CroatiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Osijek University Hospital
- Trial code
- NCT07422974
- Record updated
- 20 February 2026
- Original description
This prospective study investigates the effects of neoadjuvant therapy on endothelial function, microvascular tissue density, and tissue fibrosis in patients with colorectal cancer and their association with perioperative complications. The primary objective is to assess differences in microvascular tissue density between patients who received neoadjuvant therapy and those who did not, biomarkers, and demographic factors between patients who received neoadjuvant therapy and those who underwent surgery as initial treatment, and to compare clinical outcomes. The study will include 34 patients treated with neoadjuvant therapy and 34 patients for whom surgery is the first-line treatment. Patients will be followed until discharge from the hospital, and complications after discharge will be monitored through medical records one month after surgery.Read full original descriptionShow less
The Impact of Neoadjuvant Therapy on Perioperative Complications and Treatment Outcomes in Patients Undergoing Colorectal Cancer Resection
This prospective study investigates the effects of neoadjuvant therapy on endothelial function, microvascular tissue density, and tissue fibrosis in patients with colorectal cancer and their association with perioperative complications. The primary objective is to assess differences in microvascular tissue density between patients who received neoadjuvant therapy and those who did not, biomarkers, and demographic factors between patients who received neoadjuvant therapy and those who underwent surgery as initial treatment, and to compare clinical outcomes. The study will include 34 patients treated with neoadjuvant therapy and 34 patients for whom surgery is the first-line treatment. Patients will be followed until discharge from the hospital, and complications after discharge will be monitored through medical records one month after surgery.
Inclusion: Adults aged ≥18 years with histologically confirmed colorectal cancer; Planned surgical treatment for colorectal cancer (either laparoscopic LPSC or open laparotomy); Ability to understand the study protocol and provide written informed consent; Both sexes; ASA classification II or III; Patients who received neoadjuvant therapy is investigational group and patients who did not receive neoadjuvant therapy is control group.
Exclusion: Emergency surgical cases; Patients on chronic corticosteroid therapy; Age <18 years; Patients who are not conscious, not oriented, or unable to provide informed consent; Patients unable to understand the study protocol.